



## A REVIEW ON CRP ANALYSIS AND OBESITY INFLUENCE IN THE DISPARITY OF COVID-19 PANDEMIC

Moussa Mohammed Elamin<sup>1\*</sup>

1. Department of Exact Sciences, Faculty of Chemistry, University of Tahri Mohamed, Bechar, Algeria.

### ARTICLE INFO

#### Received:

28 Nov 2021

#### Received in revised form:

15 Feb 2022

#### Accepted:

17 Feb 2022

#### Available online:

28 Feb 2022

**Keywords:** C-reactive protein analysis, Coronavirus COVID-19 pandemic, Obesity, Immunity system, SARS-CoV-2 Infection

### ABSTRACT

At the current time, obesity itself can be a pandemic for many risk factors such as what is occurring in western countries were quickly comforted by the increase in the frequency of obesity, whose effects on health were soon manifested by a significant increase in cardiovascular disease in the general population. Inflammatory proteins can be classified according to their functions into different categories, although they are mainly involved in the response of the acute phase of inflammation, among which is the C-reactive protein (CRP). This study aimed to provide the effects of obesity according to the inflammatory analysis with CRP test on obese patients having a high-frequency inflammation which is one of several causes lead toward the infection and catching by Coronavirus COVID-19 disease because the influence of the obesity on the immunity system, according to sex, ethnicity, and age. We focused that obese patients must avoid any high-level CRP concentration to prevent them from any risk factors of contamination by COVID-19 pandemic.

Copyright © 2013 - All Rights Reserved - Pharmacophore

**To Cite This Article:** Elamin MM. A Review on CRP Analysis and Obesity Influence in the Disparity of COVID-19 Pandemic. *Pharmacophore*. 2022;13(1):48-55. <https://doi.org/10.51847/b3k4cePnIA>

### Introduction


Regionally, the economic development and industrialization of Western countries were accompanied by an intense rise in the occurrence of obesity. The effects of obesity on health manifested as a significant increase in cardiovascular disease, which has become the leading cause of death in these countries [1, 2]. Some studies have even concluded that the duration of obesity is more important than its severity; several surveys indicate that excessive dietary fat intake is associated with a qualitative dietary imbalance (excess of saturated fatty acids and cholesterol, ratio of n-6 and n-3 polyunsaturated fatty acids too high) contributes to the increase in the prevalence of obesity [3, 4]. Currently, it is recognized that obesity is associated with a chronic inflammatory state characterized by abnormal production of pro-inflammatory cytokines (TNF- $\alpha$  and IL-6) and increased circulating levels of markers of systemic inflammation such as CRP [5]. Some authors suggest that this chronic inflammatory state could be at the root of cardiometabolic alterations such as endothelial dysfunction or insulin resistance observed in obese individuals [6]. A basic repertoire of responses to taste stimuli is in place from birth in higher mammals [7, 8].

This repertoire evolves and is developed over the course of life mainly due to an automatic and unconscious mechanism of Pavlovian learning of food tastes. Through this mechanism, the sensory characteristics of the food become a complex conditional stimulus associated with the unconditioned physiological signals that are the nutritional consequences of ingesting that food. In this way, the sensory characteristics of the food act as signals that announce and predict nutritional effects. Consumer can regulate their consumption based on this prediction. In obese people, these mechanisms do not seem to be disturbed. Only a marked taste for dietary fat appears in the obese subject [9, 10].

The current coronavirus pandemic (COVID-19) is a public health crisis that has resulted in widespread pneumonia infection. CT scans are crucial in determining the severity of the condition. Other indicators of the entry of lungs disorder disease in the severity of the current pandemic include other sensitive elements. C-reactive protein (CRP) levels can be used to diagnose pneumonia early on, and patients with severe pneumonia have elevated CRP levels (**Figure 1**) [11-14].

C reactive protein (CRP) overexpression was found during the SARS outbreak in 2002, and it was linked to respiratory dysfunctions and patient death. However, the papers' findings remained conflicting [15, 16].

**Corresponding Author:** Moussa Mohammed Elamin; Department of Exact Sciences, Faculty of Chemistry, University of Tahri Mohamed, Bechar, Algeria. E-mail: [moussa.mohammed@univ-bechar.dz](mailto:moussa.mohammed@univ-bechar.dz)



**Figure 1.** Relationship between high-level BMI and Coronavirus COVID-19 contamination risk.

*Obesity*

*Definition*

Previously, obesity has been recognized as one of the world’s major health problems. In adults, it is defined as an excess of fat mass leading to health problems. It results from an imbalance between energy intake and expenditure. It is also defined as a disorder whereby the body lipid mass is amplified compared to the available norms, which are correlated with age, sex, size, and muscle mass. The increase in lipid mass occurs by hypertrophy (increase in the average size and lipid content of each fat cell), or by hyperplasia (increase in the total number of fat cells), or a combination of these two abnormalities in the most severely obese individuals. This increased lipid mass distribution may be generalized or localized in certain regions of the body [17-19].

*Epidemiology and Classification*

In terms of nomenclature, several classifications of obesity have been proposed:

*Classifications of Obesity According to Adult Body Mass Index*

According to the World Health Organization WHO this is an epidemic of the century and should be considered as one of the major public health problems (Table 1) [20].

**Table 1.** Classification of adults according to BMI [21].

Classification (Adults)	BMI category (Kg/m <sup>2</sup> )
Insufficient weight	< 18.5
Normal weight	18.5 – 24.9
Overweight	25.0 – 29.9
Obesity	30.0 – 34.9
Class I (moderate)	35.0 – 39.9
Class II (severe)	40 and more
Class III (morbid)	40 and more

The waist circumference (TT) and hip circumference (TH) are measured with a tape measure on a standing subject when the TT/TH ratio was less than 0.9 in women and 1 in men, while obesity is defined as a Gynoid and Android in the opposite case [22]. While BMI is a good tool for screening for obesity, it does not provide information on body composition

(proportions of fat and lean body mass) or fat distribution, which can be highly variable among individuals [23]. It is now accepted that regardless of BMI, excess fat in the abdominal cavity (android obesity) is much more harmful to health than fat in the thighs and hips gynoid obesity). Android obesity, linked to the commonness of metabolic signs, is the most harmful form of obesity. In this regard, it has been demonstrated that within each BMI category, a surge in the ratio of the waist-to-thigh (index for estimating abdominal fat accumulation) is linked to a subsequent escalation in the possibility of myocardial infarction [24]. In addition, it has been observed that obese subjects with a low amount of visceral adipose tissue have a glucose tolerance similar to those of normal weight. Recently, the cross-sectional International Day for the Evaluation of Abdominal Obesity (IDEA) study also demonstrated the importance of waist circumference as a variable associated with the risk of cardiovascular disease and type 2 diabetes [25, 26]. The prevalence of obesity increases steadily with age in adults, peaking in the age group 65-69. Epidemiological and physiological analyses have shown that high-fat diets associated with a tendency to be sedentary are the causes of the progression of obesity which accompanies the development of countries and the transition from poverty to wealth [27].

#### *In the United States*

61% of people are overweight; over the past 20 years, in all age groups and sexes, the rate has been gradually escalating. The greatest increase is seen in Teenagers where it has tripled in the 2 decades [28].

#### *In Europe*

The southern European countries commonly have greater obesity levels than in northern European countries because the traditional Mediterranean diet has been replaced by foods rich in fat, sugar, and salt [29].

#### *In French*

According to the Nutritional Surveillance and Epidemiology Unit [USEN, 2007], the various studies in France (SOFRES, Institute, and INSERM) provide identical information on the increase in the prevalence of obesity. From 8.2% in 1997 to 12.4% in 2006, 5.9 million French people were obese, and this has increased in two years [30].

#### *In Spain*

Several countries in the southern region of Europe have focused their efforts primarily on food guarantees and malnutrition. Consequently, only a small number of African populations have reported obesity trends, and from the limited and fragmentary data available on obesity prevalence, it appears that obesity prevalence exists in both developing and more developed countries in the African regions, particularly among women [31].

#### *Algeria (Maghreb Region)*

Like other Maghreb countries, Algeria has not achieved food self-sufficiency and is still afflicted by undernourishment in some of its social strata. The alarming figures of the only survey recently conducted by the Ministry of Health show that 53% of women and 36% of men are overweight and obese [32].

#### *Metabolic Consequences of Obesity*

Obesity is considered as the major risk factor in the development of insulin resistance and non-insulin-dependent diabetes abdominal obesity. In particular, it has been associated with cardiovascular morbidity and mortality. Metabolic syndrome is defined by a severe set of cardiovascular risk factors such as non-insulin-dependent diabetes, hypertension, hypertriglyceridemia, and hypo-HDL-cholesterolemia. The manifestation of this syndrome is promoted by an overload of visceral fat (increased abdominal to pelvis ratio) [33].


#### *Adipose Tissue Storage Capacity*

Adipose tissue is the body's most important energy storage organ. Besides being an energy supply for other organs, it is made of triglycerides mobilized by lipolysis. In addition to releasing substrates for neo-glycogenesis (glycerol) and lipoprotein synthesis (free fatty acids), adipose tissue releases substrates for liver activities [34].

## **Materials and Methods**

### *Subjects and Patients*

Our view study involves the demographic characteristics of the patients and controls which were recorded using a questionnaire; informed consent was signed by all participants in this study. The characteristics of the obese were selected to define the following characteristics (**Figure 2**):



**Figure 2.** Schematic Summary of The Demographic Characteristics for obese patients.

#### *Determination of CRP by Immuno-Agglutination Technique*

The CRP assay was performed in serum by the immuno-agglutination technique combined with serial dilutions of two in two, using an antiserum containing anti-CRP antibodies fixed on latex particles [35, 36]. For example, Spain has allowed us to dose CRP by two types of qualitative dosing and semi-quantitative dosing [37]. The CRP-Latex elements are glazed with anti-human CRP antibodies and the CRP Latex reagent is standardized to detect serum CRP levels in the range of 6 mg/L, which is the least clinically relevant intensity. Mixing the latex reagent with serum-containing CRP results in an antigen-antibody reaction those results in readily visible agglutination within 2 minutes [38]. CRP is present or absent in a specimen based on the presence or absence of visible agglutination [39].

#### *Semi-Quantitative Analysis C-reactive Protein According to COVID-19 Cases*

The Body Mass Index (BMI) report is a typical metric for determining obesity. Increased ACE2 receptors have been found in adipose tissue, or fat, in several investigations [40, 41]. The ACE2 receptor, an enzyme found on the membranes of cells in the lungs, arteries, heart, kidneys, and intestines, has been identified as a co-receptor for the virus that causes COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2 [42-45]. As a result of the increased ACE2 receptor secretion induced by having more adipose tissue, there is a larger risk of contracting SARS-CoV-2, which can progress to a more severe form of COVID-19 [46-48]. Due to their high viral load, they may also be more prone to spread the illness to others [49, 50].

#### *Obesity's Effect on Normal Body Function*

Lower lung capacity is caused by a decreased diaphragmatic movement influence on the entire respiratory system, resulting in a drop in oxygen saturation [51, 52]. This lowers the immune response to viral infection, affecting disease progression, infection immunity, and vaccination efficacy [53]. COVID-19 causes a greater death rate in a variety of places with significant populations of people with lower socioeconomic levels and a higher prevalence of obesity [54, 55]. Obesity (BMI > 35 kg/m) was linked to increased oxygen requirements (OR 3.09) and intubation (OR 3.87) and was a significant predictor of in-hospital death (OR 3.78) [56]. A higher level of Obesity was presented in patients identified with COVID-19 weakly pneumatology functions test which has reduced lungs work. According to the Lille Intensive Care, COVID-19 and Obesity study group in France, 47.6% of COVID-19 patients admitted to intensive care were obese (BMI >30 kg/m), with 28.2% being extremely obese (BMI >35 kg/m) [57]. With increasing BMI categories, the severity of illness and the concomitant necessity for IMV increased, reaching nearly 90% in inpatients with BMI >35 kg/m [58]. Serial dilutions of two in two (1:2.1; 4.1:8; 1:16.1:32) are carried out using physiological water. For each dilution, the qualitative test procedure is

performed [59]. The serum titer is the greatest dilution with a positive result, and the CRP concentration is calculated from the last dilution with visible agglutination [60-62]. Multiplying the titer of the sensitivity limit (6mg/l) by the approximate CRP concentration [63, 64]. For example: if it is a 1/8 dilution, the concentration was expressed. Determinations of circulating cholesterol and triglyceride levels were carried out using Bio Maghreb kits based on the same principle and protocols [65-67].

## Results and Discussion

Molecular analysis of reactivity of some patients has been shown to be a useful marker of aggravation of severe COVID-19 patients; obesity is common among COVID-19 patients and contributes to poor ventilation and lower quantity of oxygen, which represent the secretion of proteins by immune system cells according to under-grade inflammation and altering of chronic state.

This review demonstrated that obesity has an inflammatory effect provided by higher levels of CRP and the importance of immune system activation and inflammatory status in obese subjects, Obesity becomes the leading non-infectious "inflammatory" disease. Furthermore, the distribution of adipose tissue appears to play a key role in the inflammatory process related to obesity.

Hyper inflammation indicated by CRP high level has also been described previously in the pathogenesis of other human coronavirus infections. The presence of markers of hyper-inflammation in this study was associated with the control for CRP levels and respiratory support for the risk of death in people with COVID-19.

## Conclusion

The elevated level of CRP analysis as an inflammatory test on obese people in the severity of viral pandemic COVID-19 they have a higher risk of contamination which severe disease and death because obesity considered as an Autonomous risk factor for Severe COVID-19. When the rate of excessive adipose tissue is higher, it also increases the risk of infection by transmitting the virus to others. This review article aims have viewed the factors of risk caused by coronavirus disease toward obese populations, which included the CRP test and populations' immune function and prevention of respiratory system.

**Acknowledgments:** We would like to acknowledge all our patients who were part of this study.

**Conflict of interest:** None

**Financial support:** None

**Ethics statement:** None

## References

1. Lobstein T, Baur L, Uauy R. Obesity in children and young people: a crisis in public health. *Obes Rev.* 2004;5(1):4-10. doi:10.1111/j.1467-789X.2004.00133.x
2. Whitlock EP, Williams SB, Gold R, Smith PR, Shipman SA. Screening and interventions for childhood overweight: a summary of evidence for the US Preventive Services Task Force. *Pediatrics.* 2005;116(1):e125-44. doi:10.1542/peds.2005-0242
3. Dietz WH, Bellizzi MC. Introduction: the use of body mass index to assess obesity in children. *Am J Clin Nutr.* 1999;70(1):123S-5S. doi:10.1093/ajcn/70.1.123s
4. Guo SS, Chumlea WC, Roche AF, Siervogel RM. Age and maturity-related changes in body composition during adolescence into adulthood. The Fels Longitudinal Study. *Int J Obes Relat Metab Disord.* 1997;21(12):1167-75. doi:10.1093/ajcn/70.1.123s
5. Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. *Bull World Health Organ.* 2007;85(9):660-70. <https://www.who.int/publications/i/item/924154693X>
6. Cole T, Bellizzi M, Flegal K, Dietz W. Establishing a standard definition for child overweight and obesity worldwide: international survey. *BMJ.* 2000;320(7244):1240-3. doi:10.1136/bmj.320.7244.1240
7. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. *Lancet.* 1992;339(8805):1318-23. doi:10.1016/0140-6736(92)91961-7
8. Bonora E. The metabolic syndrome and cardiovascular disease. *Ann Med.* 2006;38(1):64-80. doi:10.1080/07853890500401234
9. Malecka-Tendera E, Mazur A. Childhood obesity: a pandemic of the twenty-first century. *Int J Obes.* 2006;30(2):S1-3. doi:10.1038/sj.ijo.0803367

10. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. *Circulation*. 2002;105(7):804-9. doi:10.1161/hc0702.104279
11. Sahu BR, Kampa RK, Padhi A, Panda AK. C-reactive protein: a promising biomarker for poor prognosis in COVID-19 infection. *Clin Chim Acta*. 2020;509:91-4. doi:10.1016/j.cca.2020.06.013
12. Salonen EM, Vaheri A. C-reactive protein in acute viral infections. *J Med Virol*. 1981;8(3):161-7. doi:10.1002/jmv.1890080302
13. Chen CC, Lee IK, Liu JW, Huang SY, Wang L. Utility of C-reactive protein levels for early prediction of dengue severity in adults. *BioMed Res Int*. 2015;93:60-2. doi:10.1155/2015/936062
14. Bajwa EK, Khan UA, Januzzi JL, Gong MN, Thompson BT, Christiani DC. Plasma C-reactive protein levels are associated with improved outcome in ARDS. *Chest*. 2009;136(2):471-80. doi:10.1378/chest.08-2413
15. Seidell JC, Flegal KM. Assessing obesity: classification and epidemiology. *Br Med Bull*. 1997;53(2):238-52. doi:10.1093/oxfordjournals.bmb.a011611
16. Eisenstein SA, Gredysa DM, Antenor-Dorsey JA, Green L, Arbeláez AM, Koller JM. Insulin, Central Dopamine D2 Receptors, and Monetary Reward Discounting in Obesity. *Plos One*. 2015;11(1):1-20. doi:10.1371/journal.pone.0133621
17. García-Álvarez A, Serra-Majem L, Ribas-Barba L, Castell C, Foz M, Uauy R. Obesity and overweight trends in Catalonia, Spain (1992–2003): gender and socio-economic determinants. *Public Health Nutr*. 2007;10(11A):1368-78. doi:10.1017/S1368980007000973
18. World Health Organization. Global Strategy on Diet, Physical Activity and Health, 2003. Available at <http://www.who.int/hpr/global.strategy.shtml> (accessed 15 May 2021)
19. Ahmad N, Adam SI, Nawi AM, Hassan MR, Ghazi HF. Abdominal obesity indicators: Waist circumference or waist-to-hip ratio in Malaysian adults population. *Int J Prev Med*. 2016;7:82. doi:10.4103%2F2008-7802.183654
20. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet*. 2003;362(9386):777-81. doi:10.1016/S0140-6736(03)14285-7
21. Després JP. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. *Eur Heart J Suppl*. 2006;8(suppl\_B):B4-12. doi:10.1093/eurheartj/sul002
22. Balkau B, Valensi P, Eschwège E, Slama G. A review of the metabolic syndrome. *Diabetes Metab*. 2007;33(6):405-13. doi:10.1016/j.diabet.2007.08.001
23. Lemieux-Charles L, McGuire WL. What do we know about health care team effectiveness? A review of the literature. *Med Care Res Rev*. 2006;63(3):263-300. doi:10.1177%2F1077558706287003
24. Delpuech F, Dop MC. A review of young child feeding practices in Africa and the Middle East: need for improvement. WHO. 1999;1999:27-42.
25. Hurt RT, Kulisek C, Buchanan LA, McClave SA. The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists. *Gastroenterol Hepatol*. 2010;6(12):780-92. <http://www.ncbi.nlm.nih.gov/pmc/articles/pmc3033553/>
26. STABLO-BOLTRI, Delphine: Prevalence of saupods and obesity in young adults in general medicine (the SUPRA study). *Gray literature in Europe*. 2008;1(27):53-6. <http://hdl.handle.net/10068/804713>
27. Maoui A, Bouzid K. Epidemiology of Type 2 Diabetes in the Greater Maghreb. Example of Tunisia. *Systematic review of the literature*. *Tunis Med*. 2019;97(2):286-95.
28. Koçak M, Mihalopoulos N, Kubilay N. Chemical composition of the fine and coarse fraction of aerosols in the northeastern Mediterranean. *Atmos Environ*. 2007;41(34):7351-68. doi:10.1016/j.atmosenv.2007.05.011
29. Davì G, Guagnano MT, Ciabattini G, Basili S, Falco A, Marinopicolli M, et al. Platelet activation in obese women: role of inflammation and oxidant stress. *Jama*. 2002;288(16):2008-14. doi:10.1001/jama.288.16.2008
30. Dray C, Knauf C, Daviaud D, Waget A, Boucher J, Buléon M. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. *Cell Metabol*. 2008;8(5):437-45. doi:10.1016/j.cmet.2008.10.003
31. Dixon JS, Bird HA, Sitton NG, Pickup ME, Wright V. C-reactive protein in the serial assessment of disease activity in rheumatoid arthritis. *Scand J Rheumatol*. 1984;13(1):39-44. doi:10.3109/03009748409102666
32. Ziegenhagen G, Drahovsky D. Klinische: Bedeutung des c-reactive proteins. *Med Klin*. 1983;78:24-35. doi:10.1016/s0065-2776(08)60379-x
33. Hind CR, Pepys PM. The role of serum C-reactive protein (CRP) measurement in clinical practice. *Int Med*. 1984;5:112-51. doi:10.4070%2Fkjcj.2012.42.3.151
34. Carr WP. Acute-phase response. *Clin Rheum Dis*. 1983;9(1):227-39.
35. Kolb-Bachofen V. A review on the biological properties of C-reactive protein. *Immunobiology*. 1991;183(1-2):133-45. doi:10.1016/s0171-2985(11)80193-240.
36. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. *Lancet Rheumatol*. 2020;2(6):e325-31. doi:10.1016/s2665-9913(20)30127-2

37. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med.* 2020;8(5):475-81. doi:10.1016/S2213-2600(20)30079-5
38. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054-62. doi:10.1016/S0140-6736(20)30566-3
39. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* 2020;46(5):846-8. doi:10.1007/s00134-020-05991-x
40. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020;395(10223):507-13. doi:10.1016/S0140-6736(20)30211-7
41. Tu WJ, Cao J, Yu L, Hu X, Liu Q. Clinic laboratory study of 25 fatal cases of COVID-19 in Wuhan. *Intensive Care Med.* 2020;1(1):1-4. doi:10.1016/S0140-6736(20)30211-7
42. Ruan Q, Yang K, Wang W, Jiang L, Song J. Correction to Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* 2020;1(1):1-4. doi:10.1016/S0140-6736(20)30211-7
43. Lin C, Ding Y, Xie B, Sun Z, Li X, Chen Z. Asymptomatic novel coronavirus pneumonia patient outside Wuhan: the value of CT images in the course of the disease. *Clin Imaging.* 2020;63(3):7-9. doi:10.1016/j.clinimag.2020.02.008
44. Zhang J, Yu M, Tong S, Liu LY, Tang LV. Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China. *J Clin Virol: Off Publ Pan Am Soc Clin Virol.* 2020;(127):104-392. doi:10.1016%2Fj.clinimag.2020.02.008
45. Ørn S, Manhenke C, Ueland T, Damås JK, Mollnes TE, Edvardsen T. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. *Eur Heart J.* 2009;30(10):1180-6.
46. Wang L. C-reactive protein levels in the early stage of COVID-19. *Med Mal Infect.* 2020;50(4):332-4. doi:10.1136/bmj.m1091
47. Chen T, Wu DI, Chen H, Yan W, Yang D, Chen G. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ Clin Res Ed.* 2020;368:1091. doi:10.1002%2Fehf2.12266
48. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. *Arterioscler Thromb Vasc Biol.* 2003;23(11):2063-9. doi:10.1161/01.atv.0000084640.21712.9c
49. Tang Y, Huang XR, Lv J, Chung AC, Zhang Y, Chen JZ. C-reactive protein promotes acute kidney injury by impairing G1/S-dependent tubular epithelium cell regeneration. *Clin Sci.* 2014;126(9):645-59. doi:10.1042/cs20130471
50. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. *Obesity.* 2020;28(7):1195-9. doi:10.1002/oby.22831
51. Liang W, Guan W, Chen R, Wang W, Li J, Xu K. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol.* 2020;21(3):335-7.
52. Polamarasetti P, Martirosyan D. Nutrition planning during the COVID-19 pandemic for aging immunity. *Bioact Compd Health Dis.* 2020;3(7):109-23. doi:10.31989/bchd.v3i7.733
53. Galanakis CM. The food systems in the era of the coronavirus (COVID-19) pandemic crisis. *Foods.* 2020;9(4):523.
54. Polamarasetti P, Martirosyan D. Dietary deficiencies exacerbate disparity in COVID-19 and nutrition recommendations for vulnerable populations. *Bioact Compd Health Dis.* 2020;3(11):204-13. doi:10.31989/bchd.v3i11.759
55. Functional Food Center, Martirosyan D. Functional Foods and Viral Diseases. *Food Sci Publisher.* 2020;(8):229-52. doi:10.31989/ffhd.v10i11.753
56. Pinti M, Appay V, Campisi J, Frasca D, Fülöp T, Sauce D. Aging of the immune system: focus on inflammation and vaccination. *Eur J Immunol.* 2016;46(10):2286-301.
57. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *Jama.* 2020;323(16):1574-81. doi:10.1001/jama.2020.5394
58. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W. COVID-19 in persons with haematological cancers. *Leukemia.* 2020;1(1):1-9. doi:10.1038/s41375-020-0836-7
59. Gur J, Mawuntu M, Martirosyan D. FFC's advancement of functional food definition. *Funct Foods Health Dis.* 2018;8(7):385-97. doi:10.31989/ffhd.v8i7.531
60. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *Jama.* 2020;323(20):2052-9. doi:10.1001/jama.2020.6775
61. Liu XH, Lu SH, Chen J, Xia L, Yang ZG, Charles S. Clinical characteristics of foreign-imported COVID-19 cases in Shanghai, China. *Emerg Microbes Infect.* 2020;9(1):1230-2.

62. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. *J Allergy Clin Immunol.* 2020;146(1):128-36. doi:10.1016%2Fj.jaci.2020.05.008
63. Sumantri AF, Bashari MH, Tadjoeidin H, Atik N. Risk of coronavirus disease 2019 (COVID-19) infection on leukemia patients: basic science to clinical aspect. *J Adv Pharm Educ Res.* 2022;12(1):38-45. doi:10.51847/qqIktBAHB7
64. Zavalishina SY, Bakulina ED, Eremin MV, Kumantsova ES, Dorontsev AV, Petina ES. Functional changes in the human body in the model of acute respiratory infection. *J Biochem Technol.* 2021;12(1):22-6. doi:10.51847/F8mofsugnZ
65. Alahmadi YM, Al Thagfan SS. A nationwide study on the knowledge, awareness, and practices towards COVID-19 in Saudi Arabia. *Trop J Pharm Res.* 2021;20(1):161-7. doi:10.4314/tjpr.v20i1.23
66. Cubeddu LX, de la Rosa D, Ameruoso M. Antiviral and anti-inflammatory drugs to combat COVID-19: Effects on cardiac ion channels and risk of ventricular arrhythmias. *BioImpacts: BI.* 2022;12(1):9-20. doi:10.34172/bi.2021.23630
67. Yong J, Tian J, Zhao X, Yang X, Zhang M, Zhou Y. Revascularization or medical therapy for stable coronary artery disease patients with different degrees of ischemia: a systematic review and meta-analysis of the role of myocardial perfusion. *Ther Adv Chronic Dis.* 2022;13:1-12. doi:10.1177/20406223211056713